CSL Limited (ASX:CSL)
198.05
+0.71 (0.36%)
Sep 25, 2025, 2:48 PM AEST
CSL Limited Revenue
In the fiscal year ending June 30, 2025, CSL Limited had annual revenue of $15.56B USD with 5.12% growth. CSL Limited had revenue of $7.08B in the half year ending June 30, 2025, with 15.49% growth.
Revenue
$15.56B
Revenue Growth
+5.12%
P/S Ratio
4.02
Revenue / Employee
$520.26K
Employees
29,904
Market Cap
95.48B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.79B |
Telix Pharmaceuticals | 1.01B |
Ansell | 3.06B |
Mesoblast | 26.23M |
Neuren Pharmaceuticals | 218.86M |
CSL Limited News
- 5 weeks ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
- 5 weeks ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Full Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 5 weeks ago - CSL Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Australian biopharma firm CSL posts 14% rise in annual profit - Reuters
- 3 months ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
- 4 months ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire
- 5 months ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire